HilleVax, Inc. (NASDAQ:HLVX) Short Interest Down 5.6% in March

HilleVax, Inc. (NASDAQ:HLVX - Get Free Report) saw a large drop in short interest in the month of March. As of March 31st, there was short interest totalling 448,200 shares, a drop of 5.6% from the March 15th total of 474,900 shares. Approximately 2.9% of the company's stock are sold short. Based on an average daily trading volume, of 124,700 shares, the short-interest ratio is presently 3.6 days.

HilleVax Stock Down 6.5 %

NASDAQ:HLVX traded down $0.90 during midday trading on Tuesday, hitting $13.01. 52,535 shares of the company were exchanged, compared to its average volume of 122,977. The company has a fifty day simple moving average of $16.20 and a 200 day simple moving average of $14.65. HilleVax has a fifty-two week low of $9.94 and a fifty-two week high of $20.22. The company has a current ratio of 10.62, a quick ratio of 10.62 and a debt-to-equity ratio of 0.10. The company has a market capitalization of $646.60 million, a PE ratio of -4.28 and a beta of 0.65.

HilleVax (NASDAQ:HLVX - Get Free Report) last announced its quarterly earnings results on Wednesday, March 20th. The company reported ($0.78) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.02. As a group, equities analysts anticipate that HilleVax will post -3.22 earnings per share for the current fiscal year.

Insider Buying and Selling at HilleVax

In other news, CFO Shane Maltbie sold 3,576 shares of the firm's stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $14.93, for a total value of $53,389.68. Following the sale, the chief financial officer now directly owns 40,656 shares in the company, valued at approximately $606,994.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, CFO Shane Maltbie sold 3,576 shares of the firm's stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $14.93, for a total value of $53,389.68. Following the sale, the chief financial officer now directly owns 40,656 shares in the company, valued at approximately $606,994.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Aditya Kohli sold 6,000 shares of the firm's stock in a transaction on Friday, April 5th. The shares were sold at an average price of $14.44, for a total transaction of $86,640.00. Following the completion of the sale, the director now owns 789,776 shares in the company, valued at $11,404,365.44. The disclosure for this sale can be found here. Insiders sold 78,039 shares of company stock valued at $986,464,242 in the last 90 days. Company insiders own 29.30% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of HLVX. JPMorgan Chase & Co. acquired a new position in HilleVax in the second quarter valued at $76,000. Rhumbline Advisers acquired a new position in HilleVax in the second quarter valued at $187,000. Northern Trust Corp acquired a new position in HilleVax in the second quarter valued at $1,145,000. American International Group Inc. acquired a new position in HilleVax in the second quarter valued at $66,000. Finally, Millennium Management LLC acquired a new position in HilleVax in the second quarter valued at $185,000. 86.42% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a "buy" rating and issued a $28.00 price objective on shares of HilleVax in a report on Thursday, March 21st.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus and related illness. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.